ES2431643T3 - Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores - Google Patents

Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores Download PDF

Info

Publication number
ES2431643T3
ES2431643T3 ES06849865T ES06849865T ES2431643T3 ES 2431643 T3 ES2431643 T3 ES 2431643T3 ES 06849865 T ES06849865 T ES 06849865T ES 06849865 T ES06849865 T ES 06849865T ES 2431643 T3 ES2431643 T3 ES 2431643T3
Authority
ES
Spain
Prior art keywords
treatment
level
antibody
ctx
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06849865T
Other languages
English (en)
Spanish (es)
Inventor
Walter P. Maksymowych
Robert L. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
AbbVie Biotechnology Ltd
Abbott Biotech Ltd Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Biotechnology Ltd, Abbott Biotech Ltd Bermuda filed Critical AbbVie Biotechnology Ltd
Application granted granted Critical
Publication of ES2431643T3 publication Critical patent/ES2431643T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Sustainable Development (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
ES06849865T 2005-11-01 2006-10-31 Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores Active ES2431643T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73244405P 2005-11-01 2005-11-01
US732444P 2005-11-01
PCT/US2006/042564 WO2007089303A2 (en) 2005-11-01 2006-10-31 Methods and compositions for diagnosing ankylosing spondylitis using biomarkers

Publications (1)

Publication Number Publication Date
ES2431643T3 true ES2431643T3 (es) 2013-11-27

Family

ID=38327823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06849865T Active ES2431643T3 (es) 2005-11-01 2006-10-31 Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores

Country Status (21)

Country Link
US (2) US7919264B2 (enExample)
EP (2) EP1948235B1 (enExample)
JP (4) JP5198277B2 (enExample)
KR (2) KR20140012160A (enExample)
CN (2) CN103336129A (enExample)
AU (1) AU2006337105B2 (enExample)
BR (1) BRPI0618085A2 (enExample)
CA (1) CA2626804A1 (enExample)
DK (1) DK1948235T3 (enExample)
ES (1) ES2431643T3 (enExample)
HR (1) HRP20131112T1 (enExample)
IL (2) IL190964A0 (enExample)
NZ (3) NZ608431A (enExample)
PL (1) PL1948235T3 (enExample)
PT (1) PT1948235E (enExample)
RS (1) RS53055B (enExample)
RU (2) RU2438704C2 (enExample)
SG (1) SG169361A1 (enExample)
SI (1) SI1948235T1 (enExample)
TW (2) TWI424161B (enExample)
WO (1) WO2007089303A2 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
US8874477B2 (en) 2005-10-04 2014-10-28 Steven Mark Hoffberg Multifactorial optimization system and method
ES2431643T3 (es) 2005-11-01 2013-11-27 Abbvie Biotechnology Ltd Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores
EP2738178A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) * 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
KR101440795B1 (ko) 2006-06-30 2014-09-22 애브비 바이오테크놀로지 리미티드 자동 주사 장치
KR20090101893A (ko) * 2006-10-27 2009-09-29 애보트 바이오테크놀로지 리미티드 결정형 항-ｈＴＮＦ알파 항체
EP2679995A1 (en) * 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CN101848733A (zh) * 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
SG183709A1 (en) * 2007-08-08 2012-09-27 Abbott Lab Compositions and methods for crystallizing antibodies
EP2193145A4 (en) 2007-08-28 2011-05-18 Abbott Biotech Ltd COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB
US9404932B2 (en) * 2007-11-05 2016-08-02 Nordic Bioscience A/S Pathology biomarker assay
TWI661833B (zh) 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
NZ621174A (en) 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
CA2750155A1 (en) * 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-tnf.alpha. antibodiesin patients with ankylosing spondylitis
GB0902737D0 (en) * 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
US20100260940A1 (en) * 2009-04-08 2010-10-14 Mccown James Charles System and method for depositing metallic coatings on substrates using removable masking materials
BRPI1012524A2 (pt) * 2009-04-16 2020-09-29 Abbott Biotherapeutics Corp anticorpos anti-tnf-alfa e seus usos
US8636704B2 (en) 2009-04-29 2014-01-28 Abbvie Biotechnology Ltd Automatic injection device
NZ613809A (en) * 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA2777800C (en) 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US9082177B2 (en) * 2009-11-25 2015-07-14 Dental Imaging Technologies Corporation Method for tracking X-ray markers in serial CT projection images
KR101780210B1 (ko) 2009-12-15 2017-09-21 애브비 바이오테크놀로지 리미티드 자동 주사 디바이스용 개선된 발사 버튼
CN104906656B (zh) 2010-04-21 2020-01-10 艾伯维生物技术有限公司 用于治疗药剂的受控输送的可佩戴自动注射装置
CN105056232A (zh) 2010-06-03 2015-11-18 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
MX344727B (es) * 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
MX336571B (es) 2011-01-24 2016-01-25 Elcam Medical Agricultural Cooperative Ass Ltd Inyector.
CN105709312B (zh) 2011-01-24 2019-11-05 艾伯维生物技术有限公司 从注射器拆卸针罩和自动注射装置
MY166835A (en) 2011-01-24 2018-07-23 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2619713T3 (es) * 2011-11-04 2017-06-26 Adaptive Biotechnologies Corporation Clonotipos de receptores de células T compartidos entre pacientes con espondilitis anquilosante
AU2012347460B2 (en) 2011-12-09 2017-05-25 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US20140052020A1 (en) * 2012-08-15 2014-02-20 University Of Florida Research Foundation, Inc. Magnetic apparatus and methods of use
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
CA2926384A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP2970375A1 (en) 2013-03-14 2016-01-20 AbbVie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015153437A1 (en) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
KR101598296B1 (ko) 2014-04-29 2016-02-26 가톨릭대학교 산학협력단 Dna 복제수 변이를 이용한 강직성 척추염 발병 고위험도 예측용 조성물 및 이를 이용한 예측 방법
EP3155439A4 (en) 2014-06-10 2018-03-14 Crescendo Bioscience Biomarkers and methods for measuring and monitoring axial spondyloarthritis disease activity
WO2016000813A1 (en) * 2014-06-30 2016-01-07 Merck Patent Gmbh Anti-tnfa antibodies with ph-dependent antigen binding
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
WO2017058999A2 (en) 2015-09-29 2017-04-06 Crescendo Bioscience Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal
CA3207751A1 (en) 2015-09-29 2017-04-06 Laboratory Corporation Of America Holdings Biomarkers and methods for assessing psoriatic arthritis disease activity
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
DK3442657T3 (da) * 2016-04-15 2022-10-03 Esm Tech Llc Fremgangsmåde til evaluering af artikulære ledterapi
CN106290885A (zh) * 2016-07-18 2017-01-04 本·沙朗 一种血清英夫利西elisa检测试剂盒和检测方法
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN106501523A (zh) * 2017-01-17 2017-03-15 安徽同致生物工程股份有限公司 基质蛋白酶3测定试剂盒
TWI671761B (zh) * 2017-05-01 2019-09-11 臺中榮民總醫院 脊椎關節炎患者疾病活動度電子病歷管理系統
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
CN108872585A (zh) * 2018-05-08 2018-11-23 广州创尔生物技术股份有限公司 一种胶原蛋白端肽的检测方法
WO2020014330A1 (en) * 2018-07-10 2020-01-16 Academia Sinica A biomarker and target for diagnosis, prognosis and treatment of ankylosing spondylitis
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
RU2724276C1 (ru) * 2020-03-19 2020-06-22 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт ревматологии имени В.А. Насоновой" (ФГБНУ НИИР им. В.А. Насоновой) Способ экспресс-оценки риска поражения осевого скелета при ранних формах псориатического артрита
KR102573606B1 (ko) * 2021-10-14 2023-08-31 계명대학교 산학협력단 혈청 시료를 이용하여 류마티스성 질환과 강직성 척추염을 구분하여 진단하기 위한 조성물 및 키트
KR102805517B1 (ko) * 2022-12-22 2025-05-12 주식회사 셀렉소바이오 강직성 척추염 진단용 조성물, 키트 및 이의 정보제공방법
KR20250037336A (ko) 2023-09-07 2025-03-17 주식회사 류마커바이오 강직척추염 중증도 및 병리학적 골형성 활성을 진단하기 위한 조성물

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5702909A (en) 1987-11-06 1997-12-30 Washington Research Foundation Methods of detecting collagen type II degradation in vivo
US5300434A (en) 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
US6153732A (en) * 1987-11-06 2000-11-28 Washington Research Foundation Kit for detecting analyte indicative of type II collagen resorption in vivo
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
US5136248A (en) 1990-01-29 1992-08-04 Niagara Mohawk Power Corporation Method and detector for identifying insulator flashover
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
EP0636026B1 (en) 1992-04-02 2001-12-05 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
JPH07504203A (ja) 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
DE69430909T2 (de) 1993-03-19 2003-02-27 Sequenom, Inc. Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
GB9702252D0 (en) 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
US6607879B1 (en) 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US6642007B1 (en) * 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
US6423321B2 (en) * 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
BR0206160A (pt) 2001-05-25 2004-10-26 Abbott Gmbh & Co Kg Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
CN101745112A (zh) 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004042012A2 (en) 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US20040203072A1 (en) 2002-11-08 2004-10-14 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
CN1225479C (zh) * 2002-12-23 2005-11-02 马菁 肿瘤坏死因子抗体，其制备方法以及药物组合物
EP1713502A1 (de) 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20060083741A1 (en) 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
US20060194301A1 (en) 2004-10-09 2006-08-31 Doctor Bhupendra P Large-scale production of human serum butyrylcholinesterase as a bioscavenger
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US7541028B2 (en) * 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
EP1879626A4 (en) 2005-04-19 2011-03-23 Massachusetts Inst Technology AMPHIPHILIC POLYMERS AND METHOD FOR USE THEREOF
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
ES2431643T3 (es) 2005-11-01 2013-11-27 Abbvie Biotechnology Ltd Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
EP2738178A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2012586A4 (en) 2006-04-10 2010-08-18 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF ANKYLOSANTE SPONDYLARTHRITIS
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
KR101440795B1 (ko) 2006-06-30 2014-09-22 애브비 바이오테크놀로지 리미티드 자동 주사 장치
EP2500413A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
KR20090101893A (ko) 2006-10-27 2009-09-29 애보트 바이오테크놀로지 리미티드 결정형 항-ｈＴＮＦ알파 항체
EP2679995A1 (en) 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
EP2152318A4 (en) 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
CN101848733A (zh) 2007-07-13 2010-09-29 艾博特生物技术有限公司 用于肺部给予TNFα抑制剂的方法和组合物
SG183709A1 (en) 2007-08-08 2012-09-27 Abbott Lab Compositions and methods for crystallizing antibodies
EP2193145A4 (en) 2007-08-28 2011-05-18 Abbott Biotech Ltd COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
TWI661833B (zh) 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101965514A (zh) 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
NZ621174A (en) 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
EP2240581B1 (en) 2008-01-15 2016-05-11 AbbVie Inc. Improved mammalian expression vectors and uses thereof
WO2009118662A2 (en) 2008-03-24 2009-10-01 Abbott Biotechnology Ltd. Methods and compositions for treating bone loss
US9094979B2 (en) 2008-05-16 2015-07-28 Qualcomm Incorporated Load balancing in a wireless communication system
US8636704B2 (en) 2009-04-29 2014-01-28 Abbvie Biotechnology Ltd Automatic injection device
NZ613809A (en) 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
WO2011097301A2 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
CN105056232A (zh) 2010-06-03 2015-11-18 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物

Also Published As

Publication number Publication date
TW200736611A (en) 2007-10-01
PL1948235T3 (pl) 2014-01-31
RU2438704C2 (ru) 2012-01-10
US20070172897A1 (en) 2007-07-26
CN101663048A (zh) 2010-03-03
RS53055B (sr) 2014-04-30
KR20140012160A (ko) 2014-01-29
EP2357479A1 (en) 2011-08-17
JP2014013241A (ja) 2014-01-23
WO2007089303A3 (en) 2008-01-03
US7919264B2 (en) 2011-04-05
BRPI0618085A2 (pt) 2011-08-16
AU2006337105A1 (en) 2007-08-09
HRP20131112T1 (hr) 2014-01-03
TW201337266A (zh) 2013-09-16
US9086418B2 (en) 2015-07-21
TWI424161B (zh) 2014-01-21
DK1948235T3 (da) 2013-11-25
JP2009523226A (ja) 2009-06-18
IL190964A0 (en) 2008-12-29
US20120129185A1 (en) 2012-05-24
JP2012093361A (ja) 2012-05-17
HK1123199A1 (en) 2009-06-12
CN103336129A (zh) 2013-10-02
JP2015096856A (ja) 2015-05-21
SI1948235T1 (sl) 2013-12-31
SG169361A1 (en) 2011-03-30
KR20080072643A (ko) 2008-08-06
EP1948235B1 (en) 2013-08-28
WO2007089303A2 (en) 2007-08-09
RU2011126441A (ru) 2013-01-10
PT1948235E (pt) 2013-11-26
JP5198277B2 (ja) 2013-05-15
NZ608431A (en) 2014-11-28
EP1948235A4 (en) 2008-11-26
NZ595340A (en) 2013-04-26
AU2006337105B2 (en) 2013-05-02
EP1948235A2 (en) 2008-07-30
IL210876A0 (en) 2011-04-28
CA2626804A1 (en) 2007-08-09
WO2007089303A9 (en) 2009-04-23
NZ567286A (en) 2012-03-30
KR101468523B1 (ko) 2014-12-22
RU2008121880A (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
ES2431643T3 (es) Métodos para determinar la eficacia de adalimumab en sujetos que tienen espondilitis anquilosante utilizando CTX-II y MMP3 como biomarcadores
CN110651190A (zh) 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
CN110892266A (zh) 使用gfap和uch-l1的组合辅助诊断和评价人类受试者中创伤性脑损伤的方法
CN111094983A (zh) 使用胶质细胞原纤维酸性蛋白(gfap)和/或泛素羧基末端水解酶l1(uch-l1)帮助诊断和评价已遭受骨科损伤并已遭受或可能已遭受头部损伤诸如轻度创伤性脑损伤(tbi)的患者的方法
CN110383068A (zh) 评估患者样品中uch-l1状态的改进方法
CN110546513A (zh) 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
CN110506209B (zh) 尿中所测的半乳凝素3结合蛋白用于监测狼疮性肾炎严重性和进展的应用方法
CN110603449A (zh) 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
US20180280503A1 (en) Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
US20150132744A1 (en) Methods of detecting cells latently infected with hiv
AU2013201969A1 (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
CN110494752A (zh) 用早期生物标记物泛素羧基末端水解酶l1帮助诊断测定人受试者创伤性脑损伤程度的方法
HK1123199B (en) Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers
HK1159757A (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
HK40014055B (en) Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
HK40029684A (en) Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
US20110236912A1 (en) Systems and methods for characterizing lupus erythematosus